查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1611942

癌症診斷中的人工智慧市場：按組成部分、部署、癌症類型和最終用戶 - 2025-2030 年全球預測

AI in Cancer Diagnostics Market by Component (Hardware, Services, Software), Deployment (Cloud, On-Premise), Cancer Type, End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，癌症診斷領域的人工智慧市場價值為2.2038億美元，預計到2024年將達到2.6628億美元，複合年成長率為21.52%，到2030年將達到8.625億美元。

人工智慧在癌症診斷中的範圍涵蓋先進演算法和機器學習技術的整合，以提高早期檢測、診斷準確性和個人化治療策略。對人工智慧的需求源於日益增加的癌症負擔以及對更準確、更快速的診斷方法的需求。治療範圍從影像分析到預測治療結果，對醫院、研究機構和診斷實驗室等最終用戶產生重大影響。人工智慧技術進步、醫療保健支出增加以及個人化醫療意識不斷增強推動了市場成長。然而，資料隱私問題、高成本和缺乏標準化法規構成了重大挑戰。儘管存在這些障礙，新興商機包括開發用於即時癌症檢測的人工智慧驅動工具以及人工智慧與其他技術（例如用於綜合診斷的基因組學）的整合。鼓勵公司投資研究合作，以提高人工智慧模型對不同人群的準確性和適用性，並解決當前的偏見和限制。創新機會在於建立人工智慧系統，利用巨量資料進行預測分析、簡化診斷過程中的工作流程以及改善患者治療結果。此外，建構人工智慧平台，促進醫療保健提供者之間的資料共用，同時確保患者機密性，並有可能徹底改變協作照護模式。檢查人工智慧的道德使用和透明的人工智慧使用者介面可以進一步提高信任和採用率。在快速的技術進步和不斷變化的醫療保健需求的推動下，市場充滿活力和競爭，要求相關人員保持敏捷並應對新興趨勢。結合技術創新、合規性和策略性夥伴關係關係的整合策略可以釋放人工智慧在癌症診斷方面的巨大潛力，並為這一重要領域提供顯著的成長和發展機會。

主要市場統計
基準年[2023] 22038萬美元
預測年份 [2024] 26628萬美元
預測年份 [2030] 8.625 億美元
複合年成長率（%） 21.52%

市場動態：快速發展的癌症診斷人工智慧市場的關鍵市場洞察

供需的動態交互作用正在改變癌症診斷的人工智慧市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 世界人口癌症盛行率
    • 擴大全球癌症篩檢計畫的採用
    • 快速轉向非侵入性癌症診斷
  • 市場限制因素
    • 高成本且缺乏訓練有素的腫瘤科醫生
  • 市場機會
    • 提高癌症診斷技術
    • 政府投資人工智慧在癌症診斷和治療的應用
  • 市場挑戰
    • 容易遭受網路攻擊和資料外洩

波特五力：引領癌症診斷人工智慧市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對癌症診斷市場人工智慧的影響

外部宏觀環境因素在塑造癌症診斷市場人工智慧的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解癌症診斷AI市場的競爭狀況

對癌症診斷市場中人工智慧的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 癌症診斷市場AI廠商定位矩陣績效評估

FPNV 定位矩陣是評估癌症診斷​​市場人工智慧供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

為策略分析和癌症診斷建議繪製人工智慧市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對癌症診斷市場中的人工智慧進行策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界人口癌症發生率
      • 全球多個癌症篩檢計畫招募人數激增
      • 快速過渡到非侵入性癌症診斷
    • 抑制因素
      • 成本高且缺乏訓練有素的腫瘤科醫生
    • 機會
      • 癌症診斷的技術進步
      • 政府投資人工智慧在癌症診斷和治療的應用
    • 任務
      • 容易遭受網路攻擊和資料外洩
  • 市場區隔分析
    • 組件：大容量測試中心更喜歡能夠以最小錯誤執行大規模資料處理的先進硬體。
    • 癌症類型：腦腫瘤的複雜性和對腫瘤準確分類的需求正在增加基於人工智慧的診斷的重要性。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章癌症診斷中的人工智慧市場：按組成部分

  • 硬體
  • 服務
  • 軟體

第7章癌症診斷中的人工智慧市場：按發展分類

  • 雲
  • 本地

第8章以癌症類型診斷癌症的人工智慧市場

  • 腦腫瘤
  • 乳癌
  • 大腸直腸癌
  • 肺癌
  • 攝護腺癌
  • 皮膚癌

第9章癌症診斷中的人工智慧市場：按最終用戶分類

  • 癌症中心
  • 醫院

第10章：美洲癌症診斷的人工智慧市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區癌症診斷人工智慧市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章：歐洲、中東和非洲癌症診斷的人工智慧市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Okin 與默沙東合作開發利用人工智慧的癌症診斷方法
    • ConcertAI 宣布與癌症中心達成協議，透過人工智慧驅動的影像解決方案加速並轉變精準腫瘤學
    • 羅氏與 Ibex 和 Amazon Web Services 合作，加速部署人工智慧數位病理解決方案，幫助改善癌症診斷
  • 戰略分析和建議

公司名單

  • Aiosyn BV
  • Cancer Center.ai
  • ContextVision AB
  • Deep Bio Inc.
  • Google LLC by Alphabet Inc.
  • Ibex Medical Analytics Ltd.
  • International Business Machines Corporation
  • Kheiron Medical Technologies Limited
  • Lifebit Biotech Ltd
  • Lunit Inc.
  • Medial EarlySign
  • Microsoft Corporation
  • Mindpeak GmbH
  • Paige AI, Inc.
  • PathAI, Inc.
  • Proscia Inc.
  • Qritive
  • Quantib BV
  • ScreenPoint Medical BV
  • Siemens Healthineers AG
  • Tempus Labs, Inc.
  • Therapixel
  • Visiopharm A/S
  • Viz.ai
  • Xavor Corporation
Product Code: MRR-B16853776A7C

The AI in Cancer Diagnostics Market was valued at USD 220.38 million in 2023, expected to reach USD 266.28 million in 2024, and is projected to grow at a CAGR of 21.52%, to USD 862.50 million by 2030.

The scope of AI in cancer diagnostics spans the integration of advanced algorithms and machine learning techniques to enhance early detection, diagnosis accuracy, and personalized treatment strategies. The necessity of AI arises from the growing cancer burden and the need for more precise and faster diagnostic methods. Applications range from image analysis to predicting treatment outcomes, significantly impacting end-users such as hospitals, research institutions, and diagnostic labs. Market growth is fueled by technological advancements in AI, increased healthcare expenditure, and growing awareness of personalized medicine. However, data privacy concerns, high costs, and lack of standardized regulations pose significant challenges. Despite these barriers, the latest opportunities include developing AI-driven tools for real-time cancer detection and integrating AI with other technologies such as genomics for comprehensive diagnostics. Companies are recommended to invest in research collaborations to enhance AI models' accuracy and applicability across diverse populations, addressing current biases and limitations. Innovation opportunities lie in creating AI systems that utilize big data for predictive analytics, enhancing workflow efficiency in diagnostic processes, and improving patient outcomes. Additionally, there is a promising avenue for creating AI platforms that facilitate data sharing among healthcare providers while ensuring patient confidentiality, potentially revolutionizing collaborative care models. Research into ethical AI usage and transparent AI user interfaces could further enhance trust and adoption rates. The market is dynamic yet competitive, driven by rapid technological progress and evolving healthcare needs, requiring stakeholders to stay agile and responsive to new trends. An integrated strategy combining technological innovation, compliance adherence, and strategic partnerships can unlock significant potential in AI for cancer diagnostics, offering substantial growth and development opportunities in this crucial sector.

KEY MARKET STATISTICS
Base Year [2023] USD 220.38 million
Estimated Year [2024] USD 266.28 million
Forecast Year [2030] USD 862.50 million
CAGR (%) 21.52%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving AI in Cancer Diagnostics Market

The AI in Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of cancer among the global population
    • Proliferating adoption in several cancer screening programs worldwide
    • Exponential shift towards non-invasive cancer diagnosis
  • Market Restraints
    • High cost and shortage of trained oncologists
  • Market Opportunities
    • Technological improvements in cancer diagnostics
    • Government investments in using AI in cancer diagnostics and treatments
  • Market Challenges
    • Vulnerability to cyberattacks and data breaches

Porter's Five Forces: A Strategic Tool for Navigating the AI in Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the AI in Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the AI in Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the AI in Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the AI in Cancer Diagnostics Market

A detailed market share analysis in the AI in Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the AI in Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the AI in Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the AI in Cancer Diagnostics Market

A strategic analysis of the AI in Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the AI in Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Aiosyn B.V., Cancer Center.ai, ContextVision AB, Deep Bio Inc., Google LLC by Alphabet Inc., Ibex Medical Analytics Ltd., International Business Machines Corporation, Kheiron Medical Technologies Limited, Lifebit Biotech Ltd, Lunit Inc., Medial EarlySign, Microsoft Corporation, Mindpeak GmbH, Paige AI, Inc., PathAI, Inc., Proscia Inc., Qritive, Quantib B.V., ScreenPoint Medical BV, Siemens Healthineers AG, Tempus Labs, Inc., Therapixel, Visiopharm A/S, Viz.ai, and Xavor Corporation.

Market Segmentation & Coverage

This research report categorizes the AI in Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Component, market is studied across Hardware, Services, and Software.
  • Based on Deployment, market is studied across Cloud and On-Premise.
  • Based on Cancer Type, market is studied across Brain Tumor, Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, and Skin Cancer.
  • Based on End-user, market is studied across Cancer Centers and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of cancer among the global population
      • 5.1.1.2. Proliferating adoption in several cancer screening programs worldwide
      • 5.1.1.3. Exponential shift towards non-invasive cancer diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and shortage of trained oncologists
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological improvements in cancer diagnostics
      • 5.1.3.2. Government investments in using AI in cancer diagnostics and treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Vulnerability to cyberattacks and data breaches
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Component: High-volume testing centers prefer advanced hardware that can handle large-scale data processing with minimal error
    • 5.2.2. Cancer Type: Rising significance of AI-driven diagnostic for brain tumors due to complexity & critical need for precise tumor classification
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. AI in Cancer Diagnostics Market, by Component

  • 6.1. Introduction
  • 6.2. Hardware
  • 6.3. Services
  • 6.4. Software

7. AI in Cancer Diagnostics Market, by Deployment

  • 7.1. Introduction
  • 7.2. Cloud
  • 7.3. On-Premise

8. AI in Cancer Diagnostics Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Brain Tumor
  • 8.3. Breast Cancer
  • 8.4. Colorectal Cancer
  • 8.5. Lung Cancer
  • 8.6. Prostate Cancer
  • 8.7. Skin Cancer

9. AI in Cancer Diagnostics Market, by End-user

  • 9.1. Introduction
  • 9.2. Cancer Centers
  • 9.3. Hospitals

10. Americas AI in Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific AI in Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa AI in Cancer Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Owkin Enters Collaboration Agreement With MSD to Develop AI-Powered Diagnostics for Cancer
    • 13.3.2. ConcertAI Announces Agreement with Cancer Center to Accelerate and Transform Precision Oncology Through AI-Enabled Imaging Solutions
    • 13.3.3. Roche Collaborates with Ibex and Amazon Web Services to Accelerate Adoption of AI-Enabled Digital Pathology Solutions to Help Improve Cancer Diagnoses
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aiosyn B.V.
  • 2. Cancer Center.ai
  • 3. ContextVision AB
  • 4. Deep Bio Inc.
  • 5. Google LLC by Alphabet Inc.
  • 6. Ibex Medical Analytics Ltd.
  • 7. International Business Machines Corporation
  • 8. Kheiron Medical Technologies Limited
  • 9. Lifebit Biotech Ltd
  • 10. Lunit Inc.
  • 11. Medial EarlySign
  • 12. Microsoft Corporation
  • 13. Mindpeak GmbH
  • 14. Paige AI, Inc.
  • 15. PathAI, Inc.
  • 16. Proscia Inc.
  • 17. Qritive
  • 18. Quantib B.V.
  • 19. ScreenPoint Medical BV
  • 20. Siemens Healthineers AG
  • 21. Tempus Labs, Inc.
  • 22. Therapixel
  • 23. Visiopharm A/S
  • 24. Viz.ai
  • 25. Xavor Corporation

LIST OF FIGURES

  • FIGURE 1. AI IN CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. AI IN CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AI IN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. AI IN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AI IN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AI IN CANCER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. AI IN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. AI IN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023